Abstract 237P
Background
The purpose of this paper is to report the dosimetric effects of conscious sparing of contralateral lobe of thyroid gland in select head and neck patients receiving intensity-modulated radiotherapy to ipsilateral neck only. In unilaterally treated neck, the thyroid lobe present contralaterally is passively spared. We compared the effects of consciously sparing it and associated dosimetric results and their statistical significance.
Methods
Treatment plans of 38 buccal mucosa cancer patients, treated to ipsilateral side only, receiving same dose and fractionation to buccal mucosa & elective neck irradiation were evaluated. Since October 2021 we adopted a department protocol of conscious sparing of contralateral thyroid in unilaterally treated head and neck cancer patients. 19 of these had conscious sparing of contralateral thyroid (group A) whereas 19 of old plans were evaluated when C/L thyroid were not given constraints & are being passively spared due to location on contralateral/non treatment side of neck (group B). Treatment planning was done using 7 beam (6 MV) IMRT in Eclipse 13.7 TPS in all of these patients. The best treatment plans were selected ensuring 95% PTV dose coverage and acceptable dose to organs at risk (OARs). Uniform contouring, plan optimization and evaluation protocols were followed for all of these patients.
Results
The mean dose of thyroid in group A was 10.23Gy whereas in group B it was 19.35Gy which is statistically significant (P value – 0.0001). The mean thyroid volume in group A was 4.76cc and in group B was 5.86cc which is not significant statistically different from group B, thyroid dose. Table: 237P
Groups | No. | Mean ± SD | ‘t’ value | P value |
Thyroid dose with constraint | 19 | 10.23 ± 2.18 | 9.004, df=36 | 0.0001* |
Thyroid dose without constraint | 19 | 19.35 ± 3.84 |
Unpaired ‘t’ test applied. P value = 0.0001, Significant
Conclusions
Unilateral treatment of neck passively reduces dose to OARs present on the contralateral side. This study emphasizes that conscious sparing of contralateral thyroid lobe can further reduce the dose to significant levels. This reduction can preserve thyroid function further. Larger clinical trials are required to corroborate this dosimetric gain with clinical thyroid function preservation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
154P - Can urine cytology predict variants of bladder cancer?
Presenter: Hikaru Mikami
Session: Poster viewing 03
155P - Search for circulating tumor cells in patients with urothelial cancer
Presenter: Irina Kruglova
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03